Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07332533 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Name: A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer — clinical trial record (NCT07332533)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2/3

SponsorShanghai JMT-Bio Inc.

Started2025-12-30

View on ClinicalTrials.gov ↗

Shanghai JMT-Bio Inc.

31 trials monitored

See all monitored trials

Gastric Cancer

1,194 trials monitored

See 60 trials at risk

HER2-Positive Cancer

324 trials monitored

See 21 trials at risk

This study is designed to compare the efficacy and safety of KN026 combined chemotherapy with or without Enlonstobart versus Trastuzumab combined chemotherapy with or without Pembrolizumab as first-line treatment in HER2-positive unresectable locally advanced or metastatic gastric cancer.

Trial Details

NCT Number	NCT07332533
Lead Sponsor	Shanghai JMT-Bio Inc.
Conditions	HER2-positive Gastric Cancer
Enrollment	490 participants
Start Date	2025-12-30
Primary Completion	2032-06-30 (estimated)
Study Completion	2032-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-12